Kinnate Biopharma Inc.
Kinnate Biopharma Inc.（KNTE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · KNTE · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Kinnate Biopharma Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
KNTE 季度内部人买卖趋势
KNTE 内幕交易卖出 · KNTE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
KNTE 高管卖出股份 · KNTE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 3, 2024 | Tananbaum James B. Director | Other | 520,711 | $1.35M⚡ | Form 4 |
| Apr 3, 2024 | Farzan Nima CHIEF EXECUTIVE OFFICER · Director | Other | 2,186 | $6K | Form 4 |
| Apr 3, 2024 | Krishnamohan Neha CHIEF FINANCIAL OFFICER | Other | 64,087 | $166K | Form 4 |
| Apr 3, 2024 | Flaherty Keith T. Director | Other | 66,377 | $172K | Form 4 |
| Apr 3, 2024 | Meltz Mark A COO GENERAL COUNSEL SECRETARY | Other | 27,578 | $71K | Form 4 |
| Apr 3, 2024 | GORDON CARL L Director | Other | 450,000 | $1.16M⚡ | Form 4 |
| Apr 3, 2024 | ORBIMED ADVISORS LLC Director | Other | 450,000 | $1.16M⚡ | Form 4 |
| Apr 3, 2024 | Foresite Capital Management IV, LLC 10 percent owner | Other | 520,711 | $1.35M⚡ | Form 4 |
| Mar 1, 2024 | Krishnamohan Neha CHIEF FINANCIAL OFFICER | Other | 1,506 | $4K | Form 4 |
| Mar 1, 2024 | Meltz Mark A COO GENERAL COUNSEL SECRETARY | Other | 558 | $1K | Form 4 |
| Mar 1, 2024 | Williams Richard Thomas CHIEF MEDICAL OFFICER | Other | 558 | $1K | Form 4 |
| Dec 1, 2023 | Williams Richard Thomas Chief Medical Officer | Other | 541 | $1K | Form 4 |
| Dec 1, 2023 | Krishnamohan Neha CFO | Other | 1,459 | $3K | Form 4 |
| Dec 1, 2023 | Meltz Mark A COO General Counsel Secretary | Other | 541 | $1K | Form 4 |
| Sep 1, 2023 | Krishnamohan Neha CFO | Other | 1,459 | $3K | Form 4 |
| Sep 1, 2023 | Meltz Mark A COO General Counsel Secretary | Other | 541 | $1K | Form 4 |
| Sep 1, 2023 | Williams Richard Thomas Chief Medical Officer | Other | 541 | $1K | Form 4 |
| Jun 1, 2023 | Williams Richard Thomas Chief Medical Officer | Other | 541 | $2K | Form 4 |
| Jun 1, 2023 | Meltz Mark A COO General Counsel Secretary | Other | 541 | $2K | Form 4 |
| Jun 1, 2023 | Krishnamohan Neha CFO | Other | 1,459 | $6K | Form 4 |
| May 8, 2023 | Tananbaum James B. Director | Purchase | 1,550,956 | $4.34M⚡ | Form 4 |
| May 8, 2023 | Tananbaum James B. Director | Purchase | 229,044 | $641K | Form 4 |
| May 8, 2023 | Foresite Capital Management IV, LLC 10 percent owner | Purchase | 1,550,956 | $4.34M⚡ | Form 4 |
| May 8, 2023 | Foresite Capital Management IV, LLC 10 percent owner | Purchase | 229,044 | $641K | Form 4 |
| May 4, 2023 | ORBIMED ADVISORS LLC Director | Purchase | 312,991 | $861K | Form 4 |
Foresite Capital Management IV, LLC
10 percent owner
日期
Apr 3
股数
520,711
均价
$2.59
总金额
$1.35M ⚡
Foresite Capital Management IV, LLC
10 percent owner
日期
May 8
股数
1,550,956
均价
$2.80
总金额
$4.34M ⚡
Foresite Capital Management IV, LLC
10 percent owner
日期
May 8
股数
229,044
均价
$2.80
总金额
$641K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 KNTE 内幕交易
KNTE 内幕交易
Kinnate Biopharma Inc.（KNTE）内幕交易数据来源于公司内部人（包括KNTE）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。KNTE内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Kinnate Biopharma Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
KNTE 内幕交易 · 5个问题Kinnate Biopharma Inc.（KNTE）的内部人包括高管和董事，如KNTE等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026